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Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S253regimen consisting of busulphan, melphalan and ﬂudar-
abine. All patients received ATG to prevent graft rejection.
Donors were matched related (8) andmatched unrelated (4).
BM grafts were depleted of T-cells using the soybean
agglutinin method followed by sheep RBC rosetting, and PB
grafts by immunomagnetic CD34+ selection (Isolex initially
and CliniMACS after 09/2011).
Results: Three pts died early and were not evaluable for
engraftment, the remaining 9 pts engrafted. None of these pts
developed acute or chronic GvHD after the primary graft. Of
the 9 pts evaluable for long term follow up, 8 are alive with a
median follow up time of 12.1 months (3.3-196months). One
pt relapsed 15 months post initial transplant and achieved
remission after DLI. This patient developed acute gut GVHD
that responded to steroids. Two additional pts received low
dose DLI (0.5x106CD3 cells/kg), one for recurrent viral in-
fections and the other as prophylaxis for relapse. These 2 pts
had no GvHD post-DLI. Out of the 4 pts who did not undergo
pre-transplant splenectomy, one required post transplant
splenectomy for severe persistent thrombocytopenia which
resolved post splenectomy. JAK2 mutation was not detected
post transplant in any of the 3 pts.
In this small series of pts, eight out of twelve, 66%, are
alive; two of the ﬁve pts in the subgroup cyto-reduced with
TBI based regimen and six of the seven patients in the sub-
group cyto-reduced with chemotherapy only regimen. The
causes of death were: toxicity of the preparative regimen
(TBI) in 2, intra-cranial hemorrhage in 1 and unknown in the
4 thpatient who died more than 2 years post transplant with
no evidence of disease.
Conclusions: TCD transplantation can offer long term cure
for patients with advanced chronic MF and with no evidence
of GvHD in this small cohort of patients. The early experience
at MSKCCwith TCD transplant was associatedwith high rates
of early mortality likely related to the high intensity condi-
tioning regimen containing TBI. The current regimen of
busulphan, melphalan, ﬂudarabine and ATG has been well
tolerated and the majority of pts are alive and disease free.393
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Aim: Multicenter phase II study has been conducted to
investigate whether myeloablative dose of intravenous
busulfan (ivBu) can be used for elderly recipients.
Method: This study started in September 2009, and 32
centers participated (Trial identiﬁer: UMIN000002426). Pa-
tients aged from 55 to 70with acutemyeloid leukemia (AML)
or myelodysplastic syndrome (MDS) who were planned for
allo-SCT (bone marrow (BM), peripheral blood (PB), and cord
blood (CB)) were enrolled. Pretransplant conditioining con-
sisted of 30 mg/m2 of ﬂudarabine (Flu) for 6 days (total 180
mg/m2) and 3.2 mg/kg of ivBu for 4 days (divided by 4 daily,
total 12.8 mg/kg) with or without total body irradiation
depending on type of donor cells. Calcineurine inhibitors +
methotrexate for BM or PB recipients, and tacrolimus +
mycophenolate mofetil were used for CB recipients.
Result: Thirty-eight patients were enrolled. Median age was
60 (55-68), 22 male and 16 female, 31 AML and 7 MDS were
included. Donors were 8 matched and 2 1-Ag/allele-mis-
matched related BM/PB, 8 matched and 4 1-Ag/allele-mis-
matched unrelated BM, and 16 CB (2-Ag-mismatched).
There was 1 whose total dose of ivBu was reduced (11.2 mg/
kg) due to neurotoxicity (grade III). Thirty-ﬁve achieved
neutrophil recovery (median day 17 (range, 11-45)). There
was 1 who died from NRM early before engraftment (CB
recipient, day 27) due to cerebral hemorrhage, and were 2
who failed to engraft (both CB recipients, one due to early
relapse, and the other due to rejection). There were 2 VOD/
SOS observed. Cumulative incidences of grade II-IV and III-IV
acute GVHD were 37% and 16%, respectively. With respect to
donor type, no grade III-IV acute GVHD was observed in
transplants from matched related donors. Cumulative
incidence of total chronic GVHD was 38%. Up to 24 months
post-transplant, there were 11 relapse, and 7 non-relapse
mortality. Cumulative incidences of non-relapse mortality
and relapse at 2-year post-transplant were 21% and 31%,
respectively. Overall and event-free survivals were estimated
to be 58 % and 53 % at 2 year post-transplant.
Conclusions: Myeloablative conditioning using Flu/ivBu12.8
mg/kg +/- TBI was well tolerated with acceptable low toxic-
ities and was sufﬁcient to allow donor cell-engraftment post
allo-SCT for elderly patients with AML or MDS. Given the
promising results of OS and PFS, phase II studies in much
larger scale are now under investigation.394
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Background: Inﬂuenza is one of the most common virus
causing respiratory tract infection in HM patients and HSCT
recipients. Severely immunocompromised pts suffer more
severe disease, prolonged viral shedding, emergence of
resistance as well as highermortality rate. Studies comparing
characteristics and outcomes of pandemic H1N1 and
